文献速递消化道肿瘤放疗放疗物理与技术

UGT1A1*28基因型指导的每周伊立替康联合卡培他滨新辅助放化疗治疗局部晚期直肠癌的I期研究

Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer.
PubMed 文献 · Radiother Oncol · 2017-12-19

该I期研究在局部晚期直肠癌患者中,根据UGT1A1*28基因型(*1*1或*1*28)进行每周伊立替康联合卡培他滨新辅助放化疗的剂量递增,固定卡培他滨剂量为625 mg/m2,IMRT全盆腔50 Gy/25次。*1*1基因型最大耐受剂量为80 mg/m2,*1*28基因型为65 mg/m2,常见3-4级毒性为中性粒细胞减少和腹泻。

要点

  • UGT1A1*28基因型可指导每周伊立替康联合卡培他滨放化疗的剂量选择。
  • *1*1基因型患者伊立替康最大耐受剂量为80 mg/m2,*1*28基因型为65 mg/m2。
  • 常见3-4级毒性为中性粒细胞减少和腹泻。

核心结论

  • 在UGT1A1*28基因型指导下,每周伊立替康联合卡培他滨新辅助放化疗的较高剂量是可行的,值得进一步临床试验。

主要发现

  • 每周伊立替康剂量在*1*1基因型患者中递增至95 mg/m2,在*1*28基因型患者中递增至80 mg/m2。
  • 剂量限制性毒性(DLT)在95 mg/m2的*1*1患者中观察到2/2例,在80 mg/m2的*1*28患者中观察到2/3例。
  • 80 mg/m2的*1*1患者中3例均无DLT,65 mg/m2的*1*28患者中6例有1例DLT。
  • 因此,*1*1和*1*28基因型患者的最大耐受剂量(MTD)分别为80 mg/m2和65 mg/m2。
  • 最常见的3-4级毒性为中性粒细胞减少和腹泻。

关键数值与推荐

  • 卡培他滨固定剂量为625 mg/m2,IMRT全盆腔总剂量50 Gy/25次。
  • 每周伊立替康起始剂量为50 mg/m2,*1*1基因型MTD为80 mg/m2,*1*28基因型MTD为65 mg/m2。

临床怎么用

  • 对局部晚期直肠癌患者,可根据UGT1A1*28基因型选择每周伊立替康联合卡培他滨放化疗的剂量:*1*1基因型80 mg/m2,*1*28基因型65 mg/m2。

局限性

  • 本研究为I期剂量递增研究,样本量有限,需进一步临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to identify the maximum tolerated dose (MTD) of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation according to the UGT1A1∗28 genotype in patients with locally advanced rectal cancer. PATIENTS AND METHODS: Patients with clinical stage T3-4, N0-2 who were eligible for preoperative chemoradiotherapy were screened for the UGT1A1∗28 genotype. Twenty-six patients with either the ∗1∗1 or ∗1∗28 genotype were eligible for dose escalation of irinotecan, and patients with a ∗28∗28 genotype were excluded. The starting dose of weekly irinotecan was 50 mg/m2 for the two genotype groups, whereas the dose of capecitabine was fixed at 625 mg/m2. Intensity-modulated radiation therapy (IMRT) was applied to the whole pelvis (total dose of 50 Gy in 25 fractions). RESULTS: The dose of weekly irinotecan was escalated to 95 mg/m2 in patients with the ∗1∗1 genotype and to 80 mg/m2 in those with the ∗1∗28 genotype. Dose-limiting toxicities (DLTs) were observed in 2/2 ∗1∗1 patients at 95 mg/m2 and 2/3 ∗1∗28 patients at 80 mg/m2. No DLT cases were observed among the three ∗1∗1 patients at 80 mg/m2, and one DLT case was observed among the six patients with ∗1∗28 at 65 mg/m2. Hence, 80 mg/m2 and 65 mg/m2 were the MTDs for the two groups. The most common grade 3 to 4 toxicities were neutropenia and diarrhea. CONCLUSION: A higher dose of weekly irinotecan in combination with capecitabine-based CRT is feasible under the guidance of the UGT1A1∗28 genotype. Further clinical trials at these dose levels are warranted.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Zhu J, Li X, Shen Y, et al. Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer. Radiother Oncol. 2017. PMID: 29273261. doi:10.1016/j.radonc.2017.11.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。